The Timing of Symptomatic Pulmonary Embolism in Patients With Nonwarfarin Anticoagulants Following Elective Primary Total Joint Arthroplasty
- PMID: 32046872
- DOI: 10.1016/j.arth.2020.01.024
The Timing of Symptomatic Pulmonary Embolism in Patients With Nonwarfarin Anticoagulants Following Elective Primary Total Joint Arthroplasty
Abstract
Background: The purpose of this study is to investigate the incidence and timing of postoperative, symptomatic pulmonary embolism (PE) in patients receiving nonwarfarin treatment following primary total joint arthroplasty (TJA), to clarify the appropriate duration of postoperative VTE prophylaxis.
Methods: We retrospectively reviewed the medical records of 11,148 patients who underwent primary TJA, including total knee arthroplasty and total hip arthroplasty at our institution between January 2012 and March 2019. The median postoperative day of diagnosis of symptomatic PE and the interquartile range for day of diagnosis were determined. Multivariate Cox proportional hazards modeling was used to test the difference of timing for PE based on demographics and comorbidities.
Results: The overall 90-day rate of symptomatic PE was 0.71%. The median day of diagnosis for symptomatic PE was 3 days postoperatively (interquartile range, 2-7 days). Factors showed statistical significance on multivariate analysis in association with earlier timing of PE occurrence in patients with atrial fibrillation, diabetes mellitus, coronary heart disease, and history of stroke.
Conclusion: The vast majority of symptomatic PE occurs in the early postoperative period after TJA, and atrial fibrillation, diabetes mellitus, coronary heart disease, and history of stroke were independent factors affecting the timing of symptomatic PE.
Keywords: nonwarfarin; pulmonary embolism; timing; total hip arthroplasty; total knee arthroplasty.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Perioperative Dexamethasone is Associated With a Decreased Risk of Pulmonary Embolism and Deep Vein Thrombosis Following Total Joint Arthroplasty: An Analysis of 70,000 High-Risk Patients.J Arthroplasty. 2024 Oct;39(10):2446-2451.e1. doi: 10.1016/j.arth.2024.05.020. Epub 2024 May 10. J Arthroplasty. 2024. PMID: 38735549
-
Development and Validation of a Risk Stratification System for Pulmonary Embolism After Elective Primary Total Joint Arthroplasty.J Arthroplasty. 2016 Sep;31(9 Suppl):187-91. doi: 10.1016/j.arth.2016.02.080. Epub 2016 Mar 17. J Arthroplasty. 2016. PMID: 27067463
-
Timing of Symptomatic Pulmonary Embolism with Warfarin Following Arthroplasty.J Arthroplasty. 2015 Jun;30(6):1050-3. doi: 10.1016/j.arth.2015.01.004. Epub 2015 Jan 13. J Arthroplasty. 2015. PMID: 25648058
-
Patients Who Have a Prior History of Pulmonary Embolism Require Increased Postoperative Care Following Total Joint Arthroplasty.J Arthroplasty. 2024 May;39(5):1245-1252. doi: 10.1016/j.arth.2023.10.056. Epub 2023 Nov 2. J Arthroplasty. 2024. PMID: 37924988 Review.
-
Persistent Pulmonary Embolism Rates Following Total Knee Arthroplasty Even With Prophylactic Anticoagulants.J Arthroplasty. 2017 Dec;32(12):3833-3839. doi: 10.1016/j.arth.2017.06.041. Epub 2017 Jul 5. J Arthroplasty. 2017. PMID: 28807470 Review.
Cited by
-
LncRNA MSTRG.22719.16 mediates the reduction of enoxaparin sodium high-viscosity bone cement-induced thrombosis by targeting the ocu-miR-326-5p/CD40 axis.J Orthop Surg Res. 2023 Sep 22;18(1):716. doi: 10.1186/s13018-023-04109-5. J Orthop Surg Res. 2023. PMID: 37736740 Free PMC article.
-
Timing of adverse events in patients undergoing acute and elective hip arthroplasty surgery: a multicentre cohort study using the Global Trigger Tool.BMJ Open. 2023 Jun 9;13(6):e064794. doi: 10.1136/bmjopen-2022-064794. BMJ Open. 2023. PMID: 37295831 Free PMC article.
-
Utility of D-dimer in total joint arthroplasty.World J Orthop. 2023 Mar 18;14(3):90-102. doi: 10.5312/wjo.v14.i3.90. eCollection 2023 Mar 18. World J Orthop. 2023. PMID: 36998388 Free PMC article. Review.
-
The mechanism by which enoxaparin sodium-high-viscosity bone cement reduces thrombosis by regulating CD40 expression in endothelial cells.BMC Musculoskelet Disord. 2022 May 30;23(1):513. doi: 10.1186/s12891-022-05469-5. BMC Musculoskelet Disord. 2022. PMID: 35637498 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical